TY - JOUR A1 - Bürger, Arne A1 - Schoenfeld, Cornelia von A1 - Scheiner, Christin A1 - Seidel, Alexandra A1 - Wasserscheid, Antonia A1 - Gad, Doreya A1 - Kittel-Schneider, Sarah A1 - Romanos, Marcel A1 - Reiter, Andrea M. F. T1 - Universal prevention for non-suicidal self-injury in adolescents is scarce - A systematic review JF - Frontiers in Psychiatry N2 - Non-suicidal self-injury (NSSI) during adolescence is a high-risk marker for the development and persistence of mental health problems and has been recognized as a significant public health problem. Whereas targeted prevention has indeed shown to be effective in reducing NSSI and improve mental health problems, access to such programs is limited. By face validity, universal prevention of NSSI seems an ideal starting point for a stepped-care model to circumvent a lack of resources in the medical care system. However, it is yet unclear how effective such approaches are. Here, we provide a summary of existing work on universal prevention of NSSI in adolescents younger than 21 years based on a systematic literature search. We found that only seven studies are available. None of the programs evaluated was found to be effective in reducing the incidence or frequency of NSSI. After providing a comprehensive summary of the existing work, we evaluate the fact that existing work primarily focusses on selected/targeted prevention and on psychoeducational methods. We derive implications for future directions in the field of universal prevention of NSSI. KW - non-suicidal self-injury KW - NSSI KW - emotion regulation KW - prevention KW - universal prevention KW - adolescence KW - mental health Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-357490 VL - 14 ER - TY - JOUR A1 - Mittermeier, Sabrina A1 - Seidel, Alexandra A1 - Scheiner, Christin A1 - Kleindienst, Nikolaus A1 - Romanos, Marcel A1 - Buerger, Arne T1 - Emotional dysregulation and its pathways to suicidality in a community-based sample of adolescents JF - Child and Adolescent Psychiatry and Mental Health N2 - Objective Effective suicide prevention for adolescents is urgently needed but difficult, as suicide models lack a focus on age-specific influencing factors such as emotional dysregulation. Moreover, examined predictors often do not specifically consider the contribution to the severity of suicidality. To determine which adolescents are at high risk of more severe suicidality, we examined the association between emotional dysregulation and severity of suicidality directly as well as indirectly via depressiveness and nonsuicidal self-injury. Method Adolescents from 18 high schools in Bavaria were included in this cross-sectional and questionnaire-based study as part of a larger prevention study. Data were collected between November 2021 and March 2022 and were analyzed from January 2023 to April 2023. Students in the 6th or 7th grade of high school (11–14 years) were eligible to participate. A total of 2350 adolescents were surveyed and data from 2117 students were used for the analyses after excluding incomplete data sets. Our main outcome variable was severity of suicidality (Paykel Suicide Scale, PSS). Additionally, we assessed emotional dysregulation (Difficulties in Emotion Regulation Scale, DERS-SF), depressiveness (Patient Health Questionnaire, PHQ-9) and nonsuicidal self-injury (Deliberate Self-Harm Inventory, DSHI). Results In total, 2117 adolescents (51.6% female; mean age, 12.31 years [standard deviation: 0.67]) were included in the structural equation model (SEM). Due to a clear gender-specific influence, the model was calculated separately for male and female adolescents. For male adolescents, there was a significant indirect association between emotional dysregulation and severity of suicidality, mediated by depressiveness (β = 0.15, SE = .03, p = .008). For female adolescents, there was a significant direct path from emotional dysregulation to severity of suicidality and also indirect paths via depressiveness (β = 0.12, SE = .05, p = 0.02) and NSSI (β = 0.18, SE = .04, p < .001). Conclusions Our results suggest that gender-related risk markers in 11–14-year-olds need to be included in future suicide models to increase their predictive power. According to our findings, early detection and prevention interventions based on emotion regulation skills might be enhanced by including gender-specific adjustments for the co-occurrence of emotional dysregulation, depressiveness, and nonsuicidal self-injury in girls and the co-occurrence of emotional dysregulation and depressiveness in boys. KW - suicidality KW - emotional dysregulation KW - adolescents KW - nonsuicidal self-injury (NSSI) KW - depressiveness Y1 - 2024 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-357501 SN - 1753-2000 VL - 18 ER - TY - THES A1 - Pollerhoff, Lena Katharina T1 - Age differences in prosociality across the adult lifespan: Insights from self-reports, experimental paradigms, and meta-analyses T1 - Altersunterschiede in Prosozialität über die erwachsene Lebensspanne hinweg: Erkenntnisse aus Selbstberichten, experimentellen Paradigmen und Meta-Analysen N2 - Human prosociality, encompassing generosity, cooperation, and volunteering, holds a vital role in our daily lives. Over the last decades, the question of whether prosociality undergoes changes over the adult lifespan has gained increased research attention. Earlier studies suggested increased prosociality in older compared to younger individuals. However, recent meta-analyses revealed that this age effect might be heterogeneous and modest. Moreover, the contributing factors and mechanisms behind these age-related variations remain to be identified. To unravel age-related differences in prosociality, the first study of this dissertation employed a meta-analytical approach to summarize existing findings and provide insight into their heterogeneity by exploring linear and quadratic age effects on self-reported and behavioral prosociality. Additionally, two empirical research studies investigated whether these age-related differences in prosociality were observed in real life, assessed through ecological momentary assessment (Study 2), and in a controlled laboratory setting by applying a modified dictator game (Study 3). Throughout these three studies, potential underlying behavioral and computational mechanisms were explored. The outcome of the meta-analysis (Study 1) revealed small linear age effects on prosociality and significant age group differences between younger and older adults, with higher levels of prosociality in older adults. Explorative evidence emerged in favor of a quadratic age effect on behavioral prosociality, indicating the highest levels in midlife. Additionally, heightened prosocial behavior among middle-aged adults was observed compared to younger adults, whereas no significant differences in prosocial behavior were noted between middle-aged and older adults. Situational and contextual features, such as the setting of the study and specific paradigm characteristics, moderated the age-prosociality relationship, highlighting the importance of the (social) context when studying prosociality. For Study 2, no significant age effect on real-life prosocial behavior was observed. However, evidence for a significant linear and quadratic age effect on experiencing empathy in real life emerged, indicating a midlife peak. Additionally, across all age groups, the link between an opportunity to empathize and age significantly predicted real-life prosocial behavior. This effect, indicating higher levels of prosocial behavior when there was a situation possibly evoking empathy, was most pronounced in midlife. Study 3 presented age differences in how older and younger adults integrate values related to monetary gains for self and others to make a potential prosocial decision. Younger individuals effectively combined both values in a multiplicative fashion, enhancing decision-making efficiency. Older adults showed an additive effect of values for self and other and displayed increased decision-making efficiency when considering the values separately. However, among older adults, individuals with better inhibitory control were better able to integrate information about both values in their decisions. Taken together, the findings of this dissertation offer new insights into the multi-faceted nature of prosociality across adulthood and the mechanisms that help explain these age-related disparities. While this dissertation observed increasing prosociality across the adult lifespan, it also questions the assumption that older adults are inherently more prosocial. The studies highlight midlife as a potential peak period in social development but also emphasize the importance of the (social) context and that different operationalizations might capture distinct facets of prosociality. This underpins the need for a comprehensive framework to understand age effects of prosociality better and guide potential interventions. N2 - Menschliche Prosozialität beinhaltet Verhaltensweisen wie Großzügigkeit, Kooperation und freiwilliges Engagement und spielt eine entscheidende Rolle in unserem täglichen Leben. In den letzten Jahrzehnten hat die Frage, ob sich Prosozialität über die erwachsene Lebensspanne hinweg verändert, zunehmende Bedeutung in der Forschung erfahren. Frühere Studien zeigten eine erhöhte Prosozialität bei älteren im Vergleich zu jüngeren Erwachsenen. Meta-Analysen zeigten jedoch, dass dieser Alterseffekt heterogen und geringfügig sein könnte. Zusätzlich sind die Faktoren und Mechanismen, die zu diesen altersbedingten Veränderungen beitragen, noch wenig verstanden. Um die altersbedingten Unterschiede in Prosozialität besser zu charakterisieren, wurde in der ersten Studie dieser Dissertation ein meta-analytischer Ansatz verfolgt, um vorhandene Forschungsergebnisse systematisch zusammenzufassen und Einblicke in die zugrundeliegende Heterogenität zu erhalten. Hierfür wurden lineare und quadratische Alterseffekte auf selbstberichtete und verhaltensbezogene Prosozialität untersucht. Zusätzlich untersuchten zwei empirische Studien, ob diese altersbedingten Unterschiede in prosozialem Verhalten auch im realen Leben durch „ecological momentary assessment“ (wiederholte Selbstberichte im Alltag; Studie 2) und in einer kontrollierten Laboruntersuchung mittels eines modifizierten Diktator-Spiels (Studie 3) beobachtbar sind. Im Rahmen dieser drei Studien wurden zudem potenzielle zugrundeliegende Verhaltens- und komputationale Mechanismen untersucht. Die Ergebnisse der Meta-Analyse (Studie 1) zeigten einen geringfügigen linearen Anstieg von Prosozialität über das erwachsene Alter hinweg und signifikante Unterschiede zwischen jüngeren und älteren Erwachsenen, wobei ältere Erwachsene prosozialer waren. Zusätzlich zeigte eine explorative Analyse einen quadratischen Effekt von Alter auf prosoziales Verhalten, mit den höchsten Werten im mittleren Erwachsenenalter. Darüber hinaus verhielten sich mittelalte Erwachsene prosozialer im Vergleich zu jüngeren Erwachsenen, während keine signifikanten Unterschiede zwischen mittelalten und älteren Erwachsenen gefunden wurden. Situative und kontextuelle Merkmale, wie beispielsweise das Setting der Studie und bestimmte Merkmale des Paradigmas, moderierten den Zusammenhang zwischen Alter und Prosozialität und heben damit die Bedeutung des (sozialen) Kontextes bei der Untersuchung von Prosozialität hervor. Studie 2 konnte keinen signifikanten Zusammenhang zwischen Alter und prosozialem Verhalten im realen Leben finden. Es zeigte sich jedoch ein signifikanter linearer und quadratischer Alterseffekt auf das Erleben von Empathie im realen Leben, mit den höchsten Werten im mittelern Erwachsenenalter. Zudem zeigte sich, dass der Zusammenhang zwischen der Möglichkeit, in einer Situation Empathie zu empfinden, und dem Alter das Ausmaß an prosozialem Verhalten im realen Leben vorhersagte. Dieser Effekt, d.h. ein höheres Maß an prosozialem Verhalten in Situationen, die Empathie auslösen, war am stärksten im mittleren Erwachsenenalter ausgeprägt. In Studie 3 hingegen wurden Altersunterschiede in der Art und Weise beobachtet, wie ältere und jüngere Erwachsene die Werte potenzieller Gewinne für sich selbst versus für eine andere Person berücksichtigen, um eine mögliche prosoziale Entscheidung zu treffen. Jüngere Erwachsene kombinierten beide Werte auf multiplikative Weise, was zu einer erhöhten Entscheidungseffizienz führte. Ältere Erwachsene zeigten hingegen einen additiven Effekt der Werte für sich selbst und die andere Person auf ihre Entscheidungen und waren effizienter in ihrer Entscheidungsfindung, wenn sie die Werte separat betrachteten. Eine stärkere inhibitorische Kontrolle ermöglichte es älteren Erwachsenen, Informationen beider Werte in ihre Entscheidungsprozesse einzubeziehen. Die Ergebnisse dieser Dissertation liefern wertvolle Erkenntnisse zur vielschichtigen Natur der Prosozialität über die erwachsene Lebensspanne hinweg sowie zu den Mechanismen, die diese altersbedingten Unterschiede erklären können. Obwohl die Ergebnisse eine Zunahme an Prosozialität mit dem Alter stützen, hinterfragen sie auch die Annahme, dass ältere Erwachsene grundsätzlich prosozialer sind. Die einzelnen Studien setzen die Lebensmitte als möglichen Höhepunkt der sozialen Entwicklung in den Fokus, betonen aber auch die Bedeutung des (sozialen) Kontexts sowie die Tatsache, dass unterschiedliche Operationalisierungen möglicherweise unterschiedliche Facetten der Prosozialität erfassen. Dies hebt die Notwendigkeit einer umfassenden Übersichtsarbeit hervor, um Alterseffekte von Prosozialität besser verstehen und mögliche Interventionen erarbeiten zu können. KW - Altersunterschied KW - prosocial behavior KW - adult development KW - prosociality KW - older adults KW - Lebenslauf KW - Metaanalyse KW - prosocial Y1 - 2024 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-359445 ER - TY - JOUR A1 - Gschmack, Eva A1 - Monoranu, Camelia-Maria A1 - Marouf, Hecham A1 - Meyer, Sarah A1 - Lessel, Lena A1 - Idris, Raja A1 - Berg, Daniela A1 - Maetzler, Walter A1 - Steigerwald, Frank A1 - Volkmann, Jens A1 - Gerlach, Manfred A1 - Riederer, Peter A1 - Koutsilieri, Eleni A1 - Scheller, Carsten T1 - Plasma autoantibodies to glial fibrillary acidic protein (GFAP) react with brain areas according to Braak staging of Parkinson’s disease JF - Journal of Neural Transmission N2 - Idiopathic Parkinson’s disease (PD) is characterized by a progredient degeneration of the brain, starting at deep subcortical areas such as the dorsal motor nucleus of the glossopharyngeal and vagal nerves (DM) (stage 1), followed by the coeruleus–subcoeruleus complex; (stage 2), the substantia nigra (SN) (stage 3), the anteromedial temporal mesocortex (MC) (stage 4), high-order sensory association areas and prefrontal fields (HC) (stage 5) and finally first-order sensory association areas, premotor areas, as well as primary sensory and motor field (FC) (stage 6). Autoimmunity might play a role in PD pathogenesis. Here we analyzed whether anti-brain autoantibodies differentially recognize different human brain areas and identified autoantigens that correlate with the above-described dissemination of PD pathology in the brain. Brain tissue was obtained from deceased individuals with no history of neurological or psychiatric disease and no neuropathological abnormalities. Tissue homogenates from different brain regions (DM, SN, MC, HC, FC) were subjected to SDS-PAGE and Western blot. Blots were incubated with plasma samples from 30 PD patients and 30 control subjects and stained with anti-IgG antibodies to detect anti-brain autoantibodies. Signals were quantified. Prominent autoantigens were identified by 2D-gel-coupled mass spectrometry sequencing. Anti-brain autoantibodies are frequent and occur both in healthy controls and individuals with PD. Glial fibrillary acidic protein (GFAP) was identified as a prominent autoantigen recognized in all plasma samples. GFAP immunoreactivity was highest in DM areas and lowest in FC areas with no significant differences in anti-GFAP autoantibody titers between healthy controls and individuals with PD. The anti-GFAP autoimmunoreactivity of different brain areas correlates with the dissemination of histopathological neurodegeneration in PD. We hypothesize that GFAP autoantibodies are physiological but might be involved as a cofactor in PD pathogenesis secondary to a leakage of the blood–brain barrier. KW - Parkinson KW - GFAP KW - autoantibodies KW - Braak Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-325161 VL - 129 IS - 5-6 ER - TY - JOUR A1 - Fekete, Stefanie A1 - Egberts, K. A1 - Preissler, T. A1 - Wewetzer, C. A1 - Mehler-Wex, C. A1 - Romanos, M. A1 - Gerlach, M. T1 - Estimation of a preliminary therapeutic reference range for children and adolescents with tic disorders treated with tiapride JF - European Journal of Clinical Pharmacology N2 - Purpose Tiapride is commonly used in Europe for the treatment of tics. The aim of this study was to examine the relationship between dose and serum concentrations of tiapride and potential influential pharmacokinetic factors in children and adolescents. In addition, a preliminary therapeutic reference range for children and adolescents with tics treated with tiapride was calculated. Methods Children and adolescents treated with tiapride at three university hospitals and two departments of child and adolescents psychiatry in Germany and Austria were included in the study. Patient characteristics, doses, serum concentrations, and therapeutic outcome were assessed during clinical routine care using standardised measures. Results In the 49 paediatric patients (83.7% male, mean age = 12.5 years), a positive correlation was found between tiapride dose (median 6.9 mg/kg, range 0.97–19.35) and serum concentration with marked inter-individual variability. The variation in dose explained 57% of the inter-patient variability in tiapride serum concentrations; age, gender, and concomitant medication did not contribute to the variability. The symptoms improved in 83.3% of the patients. 27.1% of the patients had mild or moderate ADRs. No patient suffered from severe ADRs. Conclusions This study shows that tiapride treatment was effective and safe in most patients with tics. Compared with the therapeutic concentration range established for adults with Chorea Huntington, our data hinted at a lower lower limit (560 ng/ml) and similar upper limit (2000 ng/ml). KW - Tourette syndrome KW - therapeutic drug monitoring KW - serum concentration KW - paediatrics KW - pharmacokinetics Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-279893 VL - 77 IS - 2 ER - TY - GEN A1 - Fekete, Stefanie A1 - Egberts, K. A1 - Preissler, T. A1 - Wewetzer, C. A1 - Mehler-Wex, C. A1 - Romanos, M. A1 - Gerlach, M. T1 - Correction to: Estimation of a preliminary therapeutic reference range for children and adolescents with tic disorders treated with tiapride T2 - European Journal of Clinical Pharmacology N2 - Correction to: European Journal of Clinical Pharmacology (2021) 77:163–170 https://doi.org/10.1007/s00228-020-03000-0 KW - Erratum Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-329467 VL - 77 IS - 8 ER - TY - JOUR A1 - Fekete, Stefanie A1 - Kulpok, Christine A1 - Taurines, Regina A1 - Egberts, Karin A1 - Geissler, Julia A1 - Gerlach, Manfred A1 - Malonga Makosi, Dorothée A1 - König, Jochem A1 - Urschitz, Michael S. A1 - Toni, Irmgard A1 - Neubert, Antje A1 - Romanos, Marcel T1 - Value of a web-based pediatric drug information system to prevent serious adverse drug reactions in child and adolescent psychiatry JF - Journal of Neural Transmission N2 - Psychotropic drugs are frequently prescribed ‘off-label’ to children and adolescents and carry the risk of serious adverse drug reactions (sADR). We examined the frequency of sADRs of psychotropic drugs in pediatric inpatients and explored their potential preventability through following the recommendations of a web-based pediatric drug information system (PDIS). The potential socio-economic impacts of using this online system is also addressed. Routine clinical data from all inpatients treated in a child and adolescent psychiatry department between January 2017 and December 2018 were retrospectively examined for the occurrence of sADRs as defined by the European Medicines Agency. The preventability of the sADRs was assessed based on the information of the PDIS. Furthermore, the expected prolongation of the hospital stay due to sADRs was calculated as well as the associated treatment costs. The study was supported by the Innovation Fund of the Joint Federal Committee, grant number 01NVF16021. In total, 1036 patients were screened of whom 658 (63.5%) received psychopharmacological treatment. In 53 (8.1%) of these patients 54 sADRs were documented, of which 37 sADRs were identified as potentially preventable through PDIS. Mitigating sADR through PDIS would likely have prevented prolonged hospital stays and conferred considerable savings for health insurance companies. PDIS provides systematic and evidence-based information about pediatric psychopharmacotherapy and helps to prevent prescribing errors. Therefore, PDIS is a useful tool to increase drug therapy safety in child and adolescent psychiatry. Further prospective studies are needed to confirm the results. KW - adverse effects KW - pharmacovigilance KW - drug safety KW - psychotropic drugs KW - mental health Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-324817 VL - 130 IS - 1 ER - TY - JOUR A1 - Taurines, R. A1 - Fekete, S. A1 - Preuss-Wiedenhoff, A. A1 - Warnke, A. A1 - Wewetzer, C. A1 - Plener, P. A1 - Burger, R. A1 - Gerlach, M. A1 - Romanos, M. A1 - Egberts, K. M. T1 - Therapeutic drug monitoring in children and adolescents with schizophrenia and other psychotic disorders using risperidone JF - Journal of Neural Transmission N2 - Risperidone is commonly used to treat different psychiatric disorders worldwide. Knowledge on dose–concentration relationships of risperidone treatment in children and adolescents with schizophrenia or other psychotic disorders is, however, scarce and no age-specific therapeutic ranges have been established yet. Multicenter data of a therapeutic drug monitoring service were analyzed to evaluate the relationship between risperidone dose and serum concentration of the active moiety (risperidone (RIS) plus its main metabolite 9-hydroxyrisperidone (9-OH-RIS)) in children and adolescents with psychotic disorders. Patient characteristics, doses, serum concentrations and therapeutic outcomes were assessed by standardized measures. The study also aimed to evaluate whether the therapeutic reference range for adults (20–60 ng/ml) is applicable for minors. In the 64 patients (aged 11–18 years) included, a positive correlation between daily dose and the active moiety (RIS\(_{am}\)) concentration was found (r\(_s\) = 0.49, p = 0.001) with variation in dose explaining 24% (r\(_s\)\(^2\) = 0.240) of the variability in serum concentrations. While the RIS\(_{am}\) concentration showed no difference, RIS as well 9-OH-RIS concentrations and the parent to metabolite ratio varied significantly in patients with co-medication of a CYP2D6 inhibitor. Patients with extrapyramidal symptoms (EPS) had on average higher RIS\(_{am}\) concentrations than patients without (p = 0.05). Considering EPS, the upper threshold of the therapeutic range of RIS\(_{am}\) was determined to be 33 ng/ml. A rough estimation method also indicated a possibly decreased lower limit of the preliminary therapeutic range in minors compared to adults. These preliminary data may contribute to the definition of a therapeutic window in children and adolescents with schizophrenic disorders treated with risperidone. TDM is recommended in this vulnerable population to prevent concentration-related adverse drug reactions. KW - risperidone KW - children KW - serum concentration KW - schizophrenia KW - therapeutic drug monitoring KW - pharmacovigilance Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-324833 VL - 129 IS - 5-6 ER - TY - THES A1 - Wohkittel, Christopher Philipp T1 - Untersuchung der Amphetamin- und Guanfacinkonzentrationen im Speichel als mögliche alternative Matrix für Therapeutisches Drug Monitoring T1 - Investigation of amphetamine and guanfacine concentrations in oral fluid as a potential alternative matrix for therapeutic drug monitoring N2 - Für Kinder und Jugendliche stellt die Blutentnahme im Rahmen des Therapeutischen Drug Monitorings (TDM) aufgrund der Invasivität häufig eine große physische sowie psychische Belastung dar. Diese Stresssituation kann durch Speichelsammlung aufgrund des nicht invasiven Prozederes vermieden und zusätzlich der Material-, Personal- und Zeitaufwand im Vergleich zu einer Blutentnahme minimiert werden. Da die therapeutischen Referenzbereiche in der AGNP Konsensus-Leitlinie zum TDM von Psychopharmaka nur für Serum und Plasma validiert sind, sind vergleichende Untersuchungen von alternativen Matrizes mit Serum oder Plasma sowie eine klinische Validierung essenziell für die Implementierung in die klinische Praxis. Die Zielsetzung dieser Arbeit war es daher, den Zusammenhang zwischen Speichel- und Serumkonzentrationen von Amphetamin und Guanfacin zu untersuchen, um zukünftig das Prozedere der Probenahme für TDM bei Kinder und Jugendliche unter ADHS-Pharmakotherapie durch ein nicht invasives Verfahren zu erleichtern. Zur quantitativen Bestimmung wurden zwei unterschiedliche Methoden aus der Literatur weiterentwickelt. So war es möglich, aus Speichel- und Serumproben Amphetamin mittels HPLC-FL Analytik sowie Guanfacin mittels LC-MS/MS Analytik zu quantifizieren. Die chromatographischen Methoden wurden in Anlehnung an die Richtlinien der Gesellschaft für toxikologische und forensische Chemie (GTFCh) erfolgreich validiert. Zur Untersuchung des Zusammenhangs zwischen Speichel- und Serumkonzentrationen von Amphetamin und Guanfacin bei Kinder und Jugendlichen wurde eine klinische Studie in der Klinik und Poliklinik für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie des Universitätsklinikum Würzburgs initiiert. Von 34 Probanden, die mit Lisdexamphetamin und/oder Guanfacin behandelt wurden, konnte jeweils eine korrespondierende Speichel- und Serumprobe gewonnen und quantifiziert werden. Für Amphetamin wurde belegt, dass der Speichel-pH-Wert einen erheblichen Einfluss auf die Wirkstoffverteilung, den Quotienten aus Speichel- und Serumkonzentration, hat (ρ = -0,712; P < 0,001). Dadurch konnte erstmalig unter Berücksichtigung des Speichel-pH-Wertes eine Berechnung der theoretischen Serumkonzentration aus der Speichelkonzentration durchgeführt werden. Es wurde zwar gezeigt, dass sich sowohl der Mittelwert der Differenzen durch die Berechnung theoretischen Serumkonzentration von -343 auf 12 ng/mL als auch die Anzahl der Messwert innerhalb des Akzeptanzintervalls von 20 % verbessern, jedoch war auch nach der Umrechnung die Differenz der Messwerte zu groß, sodass eine klinische Validierung für Amphetamin nicht möglich war. In dieser Studie wurde auch erstmals Guanfacin im Speichel nachgewiesen und quantifiziert, die Konzentrationen lagen zwischen 0,45 und 5,55 ng/mL und waren im Mittel dreifach niedriger als im Serum (2,36 ng/mL vs. 7,47 ng/mL; t (8) = 5,94; P < 0,001).   Die Speichelguanfacinkonzentration wies einen starken Zusammenhang mit der korrespondierenden Serumkonzentration auf (r = 0,758; P = 0,018). Obwohl ein nicht signifikanter Trend für den Einfluss des Speichel-pH-Wertes auf den Quotienten aus Speichel- und Serumkonzentration zu erkennen war, scheint dieser weniger stark ausgeprägt zu sein als bei Amphetamin und anderen basischen Arzneistoffen (r = -0,574; P = 0,106). Mit der vorliegenden Arbeit konnte zum einen gezeigt werden, dass sich die Speichelbestimmung von Amphetamin nur zum qualitativen Nachweis für TDM eignet. Zum anderen konnte gezeigt werden, dass der Speichel-pH-Wert einen geringeren Einfluss auf die Speichelkonzentration von Guanfacin zu haben scheint, als es bei Amphetamin der Fall ist, und sich Guanfacin somit potenziell für TDM in Speichel eignet. Zukünftig könnten Speichelproben zur Kontrolle der Adhärenz sowohl von Amphetamin als auch von Guanfacin verwendet werden und die Probenahme für die Patienten vereinfachen. N2 - Due to the invasive procedure, blood sampling for therapeutic drug monitoring (TDM) is often associated with high stress levels for children and adolescents, which may be avoided by non-invasive oral fluid collection. Furthermore, it may reduce material, personnel and time costs compared to blood collection. Since the therapeutic ranges of the AGNP guideline for TDM of psychotropic drugs are only validated for serum and plasma, comparative studies of alternative matrices with serum or plasma, as well as a clinical validation are essential for the implementation into clinical practice. To investigate the relationship between oral fluid and serum concentrations of amphetamine and guanfacine in children and adolescents, a clinical study was initiated at the Clinic and Polyclinic for Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy at the University Hospital of Würzburg. Therefore, corresponding oral fluid and serum samples derived from 34 subjects treated with lisdexamfetamine and/or guanfacine were collected and quantified. A significant effect of oral fluid pH on drug distribution (ρ = -0.712; P < 0.001), reported as the quotient of oral fluid to serum concentration, was observed for amphetamine. For the first time a calculation of serum concentration from oral fluid concentration, taking oral fluid pH into account, could be performed. Although the calculation improved both the mean of the differences of both methods from -343 to -12 ng/mL and the number of samples within the 20 % acceptance interval, the clinical validation was missed due to the variation between the measured and the calculated serum concentration of amphetamine. Furthermore, guanfacine was detected and quantified in oral fluid for the first time, with concentrations from 0.45 to 5.55 ng/mL, which was three times lower compared to serum concentrations (2.36 ng/mL vs. 7.47 ng/mL; t (8) = 5.94; P < 0.001). A strong relationship between oral fluid and the corresponding serum concentration of guanfacine (r = 0.758; P = 0.018) was observed. Although a non-significant trend suggested an influence of oral fluid pH on the oral fluid-to-serum concentration ratio, it appeared to be significantly less pronounced than for amphetamine and other basic drugs (r = -0.574; P = 0.106). With the herein presented work it was shown that, on the one hand, the determination of amphetamine in oral fluid may be suitable for qualitative issues in TDM, and, on the other hand, oral fluid pH seems to have a smaller influence on the oral fluid concentration of guanfacine than it is the case for amphetamine and, thus, guanfacine is promising candidate for TDM in oral fluid. In future, oral fluid could be used for compliance monitoring of amphetamine and guanfacine and to facilitate specimen collection as a non-invasive procedure for children and adolescents. KW - Pharmakotherapie KW - Aufmerksamkeitsdefizit-Syndrom KW - Blutspiegel KW - Amphetamin KW - Therpeutisches Drug Monitoring KW - Guanfacin KW - Oral Fluid KW - Therapeutic Drug Monitoring KW - Speichel Y1 - 2024 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-349635 ER - TY - THES A1 - Eckert, Lisa Doreen T1 - Multimodale Verfahren zum Eisenstoffwechsel bei ADHS - Vergleichende Bildgebung T1 - Multimodal methods for iron metabolism in ADHD - Comparative imaging N2 - Die Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) gehört weltweit zu den bedeutendsten psychiatrischen Erkrankungen des Kinder- und Jugendalters. Die Pathomechanismen sind aktuell noch nicht vollständig geklärt, wobei es deutliche Hinweise auf hirnorganische Veränderungen gibt. Die transkranielle Sonographie stellt eine nicht-invasive Methode dar, strukturelle Unterschiede tiefer Hirnstrukturen zu untersuchen. Bereits in vorangegangenen Studien konnte mit der Methode eine Veränderung der Echogenität der Substantia nigra (SN) bei Kindern mit ADHS im Vergleich zu gesunden Kontrollprobanden nachgewiesen werden. In dieser Studie sollen nun die möglichen physiologischen Hintergründe der erhöhten Echogenität der Substantia Nigra in Zusammenschau mit bildgebenden Verfahren betrachtet werden. Hierzu wurde in der vorliegenden multimodalen Studie bei 20 männlichen Kindern mit ADHS im Alter zwischen 8 und 12 Jahren eine transkranielle Ultraschalluntersuchung (TCS) zur Bestimmung der echogenen Fläche der Substantia Nigra sowie ein neuromelaninsensitives cMRT zur Bestimmung des neuromelaninassoziierten Volumens der SN, sowie des neuromelaninassoziierten Kontrastes SN/Cb durchgeführt. Als Kennwerte des peripheren Eisenhaushalts wurden die Konzentrationen von Eisen, Ferritin und Transferrin im Blut bestimmt. In die Auswertung gingen außerdem die Stärke der ADHS-Symptomatik (Strength and Difficulties Questionaire, SDQ; Fremdbeurteilungsbogen bei ADHS, FBB-ADHS), die kognitive Begabung (über CFT-20-R) und das Alter der Probanden ein. Psychiatrische Komorbidität wurde mit Hilfe der Child Behaviour Checklist (CBCL) erhoben. N2 - Attention deficit/hyperactivity disorder (ADHD) is one of the most important psychiatric diseases of children and adolescents worldwide. The pathomechanisms are currently not yet fully understood, although there are clear indications of organic brain changes. Transcranial sonography is a non-invasive method, to investigate structural differences in deep brain structures. In previous studies, the method was able to demonstrate a change in the echogenicity of the substantia nigra (SN) in children with ADHD compared to healthy control subjects. This study investigates the possible physiological background of the increased echogenicity of the substantia nigra including imaging procedures. For this purpose, in the present multimodal study, a transcranial ultrasound examination (TCS) to determine the echogenic area of the substantia nigra and a neuromelanin-sensitive cMRI to detect the neuromelanin-associated volume of the SN and the neuromelanin-associated Contras SN/Cb were used in 20 male children with ADHD between the ages of 8 and 12 years. The concentrations of iron, ferritin and transferrin in the blood were determined as parameters of the peripheral iron balance. The evaluation also included the strength of the ADHD symptoms (Strength and Difficulties Questionnaire, SDQ; external assessment form for ADHD, FBB-ADHD), the cognitive ability (via CFT-20-R) and the age of the test subjects. Psychiatric comorbidity was assessed using the Child Behavior Checklist (CBCL). KW - TCS KW - Neuromelanin KW - ADHS KW - Transkranielle Sonographie KW - Aufmerksamkeitsdefizit-Syndrom KW - Zweikomponentensystem KW - Eisen Y1 - 2024 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-348295 ER -